February 26, 2025 -- InvestorsHub
NewsWire -- For 15 years, DELEX Pharma has been a leading force in
the Philippine healthcare sector, consistently delivering
high-quality pharmaceutical products and building a reputation for
excellence. With its impressive history, extensive product
offerings, and visionary expansion strategies, DELEX is poised for
unprecedented growth.
Here's a closer look at DELEX
ROADMAP, based on its strengths and strategic plans designed to
propel its success well into the future and drive innovation,
growth, market leadership in the healthcare sector.
1. 15 Years of Robust
Business Growth
DELEX Pharma’s legacy is built on
15 years of sustained growth, ranking as the third-largest national
player in the hospital channel market according to IQVIA. The
company’s leadership team, with over three decades of experience in
the healthcare sector, has played an integral role in driving this
growth and positioning DELEX as a powerhouse within the
industry.
2. Leadership That Drives
Excellence
At the helm of DELEX is a group of
seasoned leaders with extensive experience in both the
pharmaceutical and medical industries. Their entrepreneurial acumen
and expertise, honed through years of working with multinational
healthcare giants, empower DELEX to continually adapt and thrive in
a competitive market. This leadership ensures the company’s future
success as they continue to execute on their ambitious vision for
the future.
3. Holder of Various FDA
Business Licenses & Permits
From importing and distributing
pharmaceutical products to running drugstores and medical devices,
DELEX is fully equipped to meet the regulatory standards that
govern the diverse landscape of the Philippine healthcare industry.
DELEX Pharma currently holds various licenses and permits issued by
the Philippines Food and Drug administration for (i) Importer/
Wholesaler/Distributor of Drugs (ii) Importer of Medical Devices
(iii) Food Wholesaler, (iv) Cosmetic Importer and Wholesaler and
(v) Drugstore Operator, including Online Order and Delivery.
4. Holder of 30 FDA
Approved Hospital Products
DELEX Pharma is committed to
continuously expanding its product portfolio to meet the needs of
both healthcare professionals and patients. With over 30
FDA-approved hospital products and numerous medical device
products, DELEX is pushing the boundaries of innovation.
The company’s recent launch of 11 new pharmaceutical products and
strategic partnerships with multinational medical device firms
demonstrates its aggressive expansion strategy across multiple
therapeutic and diagnostic areas.
5. Expanding the
Distribution Channels
With a network that already
supplies nearly 700 hospitals nationwide and has established a
foothold in over 900 Mercury Drug branches, DELEX is positioned for
even greater reach. By building on its strong distribution network
and forming strategic partnerships with healthcare providers, DELEX
aims to expand its footprint, enhancing its market development and
creating integrated healthcare solutions to improve patient
outcomes.
6. Expanding the Medical
Device Business
The medical device market in the
Philippines is experiencing rapid growth, and DELEX is
well-positioned to capitalize on this opportunity. With a strategic
alliance with leading international companies such as Amsino,
Masimo, and Verathon, DELEX aims to be a key player in the medical
device sector. These collaborations will not only enhance DELEX’s
offerings but also solidify its position as a leading distributor
of high-quality healthcare solutions.
7. Expanding the Pharmacy
Stores
Building on the success of its
first pharmacy branch opened in 2021, DELEX plans to expand its
retail pharmacy business to 60 locations in the coming years. This
expansion comes at a time when the pharmacy market is poised for
significant growth, driven by increased demand for pharmaceutical
services and products. DELEX’s strategy of situating drugstores
near hospitals and high-traffic areas is a smart move to generate
strong sales and meet the needs of the community.
8. Expanding the Online
Pharmacy Business
As the healthcare landscape becomes
increasingly digital, DELEX is tapping into the rapidly growing
ePharmacy market. Through its online platform, DELEX offers a
seamless 24/7 ordering and delivery service for a wide range of
over-the-counter medicines, prescription drugs, and health
products. As the Philippines’ ePharmacy market continues to expand,
DELEX is set to capture a broad customer base and meet the demand
for convenient, cost-effective healthcare solutions.
9. Expand DELEX’s Training
Programs and Global Networks
DELEX has proven its commitment to
improving healthcare outcomes through educational initiatives such
as the DELEX ICU Forum. What began as an in-person event has grown
into a powerful online platform that has attracted nearly 200,000
healthcare professionals worldwide. The forum facilitates important
conversations on critical care advancements, treatment protocols,
and best practices, further solidifying DELEX’s role as a thought
leader in the healthcare space.
10. Strategic Acquisition
to Expand DELEX’s Product Portfolio
In 2022, DELEX Pharma made a
significant move to acquire JMN Brothers Pharma Limited, a company
known for its expertise in women’s health and beauty. This
acquisition enables DELEX to expand its hospital product portfolio
and tap into new market segments, further diversifying its
offerings and increasing its market share in the healthcare
sector.
11. Commitment to Quality
Through ISO Certification
DELEX Pharma’s commitment to
quality and operational excellence has been recognized globally.
The company recently underwent and passed the ISO 9001:2015
re-certification, underscoring its dedication to meeting
international quality standards and providing superior products and
services to its customers.
12. Strong Distribution and
Warehouse Capabilities
With a robust infrastructure that
includes a dedicated trade sales team and state-of-the-art SAP ERP
systems, DELEX Pharma ensures efficient distribution and inventory
management. This operational efficiency allows DELEX to respond
promptly to customer demands and maintain high levels of service
across its entire distribution network.
13. Winner of Several
Industry Awards
DELEX’s track record of success is
reflected in the numerous accolades and awards the company has
received. These include recognition as the “Diversity Company of
the Year” and “SME Company of the Year” by the Asia CEO Awards, as
well as individual honors for its leadership team. These awards
affirm DELEX’s position as a top-tier healthcare company in the
Philippines.
14. Asia’s Booming
Pharmaceutical Market
With the Asian pharmaceutical
market projected to reach US$304.8 billion by 2029, DELEX Pharma is
poised to play a key role in this rapidly growing industry. The
company’s strategic positioning and expansive product offerings
give it a competitive edge as the market continues to grow at a
steady pace.
15. Name Change and Ticker
Symbol
A formal application to rename BNCM
to DELEX and update the ticker symbol will be applied from Q1 2025,
aligning with the new direction of the merged company. This rebrand
reflects the company’s ambition to further solidify its presence in
the global healthcare market and prepare for an exciting phase of
expansion.
16. Regulation A Filing and
SEC Approval
To support its future growth, DELEX
Pharma plans to file for Regulation A with the SEC from March 2025,
opening up new avenues for investment and funding. This filing is a
crucial step in DELEX’s journey toward achieving its long-term
business objectives.
17. Uplist to OTCQB and
NASDAQ
DELEX plans to take its corporate
visibility to the next level by applying for an uplist to the OTCQB
in 2025, with the ultimate goal of listing on the NASDAQ. This move
will open the doors for increased capital access and heighten
DELEX’s visibility among global investors.
DELEX Pharma: A Future of
Growth and Innovation
With a proven track record of
success, a visionary leadership team, and a strategic expansion
plan that spans multiple facets of the healthcare industry, DELEX
Pharma is poised to become a dominant player in the global
healthcare market. As the company continues to innovate, expand,
and strengthen its presence in key sectors, it remains on track to
achieve its ambitious goals and deliver value to its stakeholders.
The future of DELEX Pharma looks brighter than ever, and investors
have a unique opportunity to be part of this dynamic journey.
For more information, visit -
https://bncm.net/
Disclaimer: The information presented in this
article is for informational purposes only and does not constitute
financial, investment, or business advice. DELEX future plans,
projections, and growth strategies are subject to various risks and
uncertainties, and actual results may differ significantly.
Investors should conduct their own research and consult with a
financial advisor before making any investment decisions. DELEX is
not responsible for any financial or investment outcomes resulting
from the use of this information.
Bounce Mobile Systems (PK) (USOTC:BNCM)
과거 데이터 주식 차트
부터 2월(2) 2025 으로 3월(3) 2025
Bounce Mobile Systems (PK) (USOTC:BNCM)
과거 데이터 주식 차트
부터 3월(3) 2024 으로 3월(3) 2025
